Clinical Trial Update: Observational Safety Study in Subjects With Type 2 Diabetes Mellitus Starting or Switching to Biphasic Insulin Aspart 30 Treatment

View source ↗

Summary

This is a completed observational safety study assessing Type 2 diabetes patients starting or switching to Biphasic Insulin Aspart 30. The sponsor is Novo Nordi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Biphasic insulin aspart 30 (insulin aspart, biphasic 30/70)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Diabetes Mellitus, Type 2 | Status: COMPLETED